Hidden Psychiatric Effects: New Findings on Adult Survivors of Childhood Leukemia Chemotherapy

A BSTRACT Chemotherapy drugs can directly affect brain function, even though they usually do not pass easily through the blood-brain barrier. Even small doses of certain agents, particularly methotrexate, can cause cell death and reduce cell division in critical brain areas like the hippocampus. Chemotherapy can weaken the barrier, making it leaky and allowing harmful signals into the brain, disrupting neural pathways and impairing memory and cognitive abilities. Childhood cancer survivors often face immediate cognitive challenges during treatment, with around 40% struggling with attention and processing speed. Those diagnosed before age 54 months have greater difficulties, leading to learning disabilities and a need for special education services. Monitoring cognitive changes is essential, as parents may notice behavioral shifts. Long-term survivors often have significant cognitive deficits and higher rates of anxiety and depression. Social interactions, friendships, and family dynamics can suffer. Younger survivors are particularly vulnerable to cognitive impairment, making proper support crucial. Drug-specific neuropsychiatric effects vary significantly, with methotrexate, corticosteroids, vincristine, and asparaginase producing different long-term psychiatric profiles. Screening for mental health in adult survivors is vital, but many have trouble accessing services due to costs. Advances in treatment focus on reducing brain damage from chemotherapy, targeting therapies, and involving families in care. Overall, the quality of life for survivors is affected by their mental, emotional, and social well-being.